Effect of empagliflozin/linagliptin on oxidative stress markers in chronic kidney patient with type 2 diabetes stage 3: A randomized, open label controlled trial
Phase 4
Completed
- Conditions
- Reactive oxidative stress in T2DM with CKD stage III with HbA1c 7-10%
- Registration Number
- TCTR20210322002
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
eGFR 30-59 ml/min/1.73m2
T2DM HbA1c 7-10%
No treatment adjusted with anti-HT within 1 months
Exclusion Criteria
T1DM or secondary diabetes
History of diabetic ketoacidosis
Current history of urinary and genital tract infection
Pancreatic and active liver disease
proliferative diabetic retinopathy
Recent smoking < 6 month
Herbal medicine use
Active infection
Active malignancy
Alzheimer disease
Pregnancy
Breast feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method urine 8OHdg baseline and 12 week ELISA
- Secondary Outcome Measures
Name Time Method ACR baseline and 12 weeks urine